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Abstract The epidemiology of benign prostatic hyperpla-
sia (BPH) and male lower urinary tract symptoms (LUTS)
has evolved considerably during the past several years. The
term LUTS describes a distinct phenotype and allows for a
broad epidemiologic description of urinary symptoms at a
population level. Although it is becoming the preferred
term for studying urinary symptoms in populations, LUTS
remains interconnected with BPH in the literature. The
incidence and prevalence of BPH and LUTS are increasing
rapidly as the US population ages. BPH and LUTS are
associated with serious medical morbidities, an increased
risk of falls, depression, diminished health-related quality
of life, and billions of dollars in annual health care costs.
Although age and genetics play important roles in the
etiology of BPH and LUTS, recent insights at the population
level have revealed that modifiable risk factors are likely key
components as well. Serum dihydrotestosterone, obesity,
elevated fasting glucose, diabetes, fat and red meat intake,
and inflammation increase the risk; vegetables, regular
alcohol consumption, exercise, and NSAIDs decrease the
risk.
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Introduction
The epidemiology of benign prostatic hyperplasia (BPH)
and male lower urinary tract symptoms (LUTS) has
evolved considerably during the past several years. The
incidence and prevalence of BPH and LUTS are increasing
rapidly as the US population ages. BPH and LUTS are
associated with serious medical morbidities, an increased
risk of falls, depression, diminished health-related quality
of life, and billions of dollars in annual health care costs.
Although age and genetics play important roles in the
etiology of BPH and LUTS, recent insights at the
population level have revealed novel risk factors that
present new opportunities for treatment and prevention.
Indeed, an exciting notion is that to a large extent, BPH and
LUTS pathogenesis may be driven by modifiable risk
factors, including serum dihydrotestosterone (DHT), obesity,
glucose homeostasis, diet, exercise, and inflammation.
Identification and Definition in Epidemiologic Studies
LUTS represent a cluster of chronic urinary disorders that
occurs among 15% to 60% of men older than 40 years of
age [1–4]. Specific symptoms associated with the LUTS
complex include frequency, urgency, nocturia, difficulty
initiating urination, sense of incomplete bladder emptying,
decreased force of stream, and interruption of stream.
The most common etiology of male LUTS is BPH. A
persistent conundrum in designing and interpreting
population-based studies of urinary symptoms in older
men is case definition. In the past, chronic urinary
symptoms in older men were uniformly ascribed to—and
defined as—BPH. There are at least two reasons why BPH
is a problematic outcome measure for population studies.
First, BPH has many different definitions, including
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histologic analysis of prostate tissue, radiographically
determined prostate enlargement, decreased urinary flow
rates, history of noncancer surgery of the prostate,
physician-diagnosed BPH, and urinary symptoms. Hetero-
geneity in defining BPH makes validation across study
populations difficult. Second, BPH excludes other potential
causes of urinary symptoms in older men, such as
interstitial cystitis and detrusor instability.
LUTS describes a distinct phenotype of a group of
disorders affecting the prostate and bladder that share a
common clinical manifestation. The term LUTS allows for
a broad epidemiologic description of urinary symptoms at a
population level without identification of organ- or disease-
specific etiologies. This approach allows consideration of
LUTS within a macroscopic context using a uniform
definition unbiased by variable definitions of BPH and
other diseases. In recent observational studies, LUTS has
become the preferred term for studying urinary symptoms in
populations [2–4]. Still, as most men with LUTS have BPH
and most men with BPH have LUTS, the two terms remain
inextricably interconnected in the contemporary treatment
and study of urinary disorders in older men. Therefore, this
review discusses BPH and LUTS as separate outcomes
describing the same spectrum of male urinary disorders.
The most commonly used measures of LUTS in
epidemiologic studies, and the primary instruments by
which BPH is diagnosed in clinical practice are the
American Urological Association Symptom Index (AUA-
SI) and its internationally validated counterpart, the
International Prostate Symptom Score (I-PSS). The AUA-
SI and I-PSS are robust and reliable quantitative instru-
ments for measuring urinary symptoms in men. As part of
its clinical guidelines, the American Urological Association
recommends the routine use of the AUA-SI or I-PSS in the
clinical evaluation of patients with suspected BPH (http://
www.auanet.org/guidelines).
Epidemiology of Lower Urinary Tract Symptoms
and Benign Prostatic Hyperplasia
Incidence and Prevalence in an Aging Population
The prevalence of BPH and LUTS rises markedly with
increased age. BPH affects 70% of US men 60–69 years
of age and 80% of those 70 years of age or older [1]. In
the Boston Area Community Health survey, LUTS
prevalence increased from 8% in men 30–39 years of
age to 35% in men 60–69 years [2]. In the Rancho
Bernardo study, 56% of men 50–79 years of age, 70% of
men 80–89 years of age, and 90% of men 90 years of age
or older reported LUTS [4]. Other population-based
studies have demonstrated similar trends [3].
LUTS incidence among older men is also considerable.
In the Osteoporotic Fractures in Men cohort, a prospective
study of 6,000 community-dwelling men older than 65 years
of age, 29% of those without LUTS at baseline developed
clinically significant LUTS within 2 years of follow-up;
among those 80 years of age or older, this proportion
increased to 34% [5]. In the Olmsted County cohort, 14%
of men without LUTS at baseline subsequently reported
moderate or severe symptoms within 18 months of follow-
up, and 22% reported moderate or severe symptoms within
42 months of follow-up [6]. Similarly, 21% of Japanese,
26% of black American, and 20% of Austrian men with no
or mild LUTS at baseline reported worsened symptoms
after 3, 4, and 5 years of follow-up, respectively [7–9]
The prevalence and incidence of BPH and LUTS in the
United States increased steadily between 1994 and 2000
(http://www.UDAonline.net). Between 1998 and 2007, the
age-adjusted prevalence of BPH among hospitalized
patients in the United States nearly doubled (Stroup and
Parsons, unpublished data). Increases in BPH and LUTS
prevalence and incidence are occurring within the context
of an aging population. By 2030, 20% of the US population
will be 65 years of age or older, a figure that will include
more than 20 million men. Significantly, the fastest-
growing segment of the older adult population is the oldest
age group: those older than 85 years of age. Current
estimates indicate that the number of individuals 80 years
of age or older in the United States will rise from 9.3
million in 2000 to 19.5 million in 2030, an increase of more
than 100% [10]. These trends portend substantial increases
in the number of incident and prevalent LUTS and BPH
cases within the next few decades.
Public Health Impact of Lower Urinary Tract Symptoms
and Benign Prostatic Hyperplasia
It is important to consider the substantial adverse
consequences of LUTS and BPH for the global health
of older men. Although it may be tempting to dismiss
LUTS and BPH as relatively harmless disorders repre-
senting more of an inexorable, if inconvenient, effect of
aging, this perception belies the substantial medical,
psychological, and economic burdens of these conditions.
Despite widespread use of medical therapy (http://www.
UDAonline.net), BPH remains associated with a substantial
prevalence of urinary infections, bladder stones, urinary
retention, and acute renal failure (Stroup and Parsons,
unpublished data). In addition, the adverse health effects of
LUTS and BPH encompass serious nonurologic conditions.
Men with severe LUTS have a 63% increased risk of falling at
least twice within 1 year compared with men with no
symptoms [11]. Falls in older adults are associated with
debilitating morbidities, including pain and fractures. LUTS
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is also associated with a significantly diminished quality of
life, depression, and impairment in instrumental activities of
daily living [3, 12].
Another important public health issue is the cost
associated with diagnosis and treatment. In 2000, the most
recent year for which comprehensive data are available,
BPH generated 1.1 billion dollars in direct health care
expenditures and accounted for more than 4.4 million office
visits, 117,000 emergency department visits, 105,000
hospitalizations, and 21 to 38 million hours in lost
productivity in the United States. During the same year,
the direct costs of treatment for overactive bladder in men
totaled 1.8 billion dollars, with another 3.9 billion dollars
directed to ancillary health care expenditures, including
treatment for urinary tract infections. Estimated annual
costs of BPH treatment currently total 3.9 billion dollars [1,
13, 14].
The high prevalence of LUTS in the older male
population, its detrimental impact on male health, and the
substantial costs associated with diagnosis and treatment
underscore the significance of this problem, particularly in
an era of rapidly increasing male longevity.
Risk Factors Associated with Lower Urinary Tract
Symptoms and Benign Prostatic Hyperplasia
On a population level, there are five broad categories of risk
factors for BPH and LUTS (Fig. 1). Aside from age, the
other categories are genetics, sex steroid hormones,
modifiable lifestyle factors, and inflammation.
Genetics
Evidence suggests that there are strong genetic components
to both BPH and LUTS. One case-control analysis, in
which participants were men younger than 64 years of age
who underwent surgery for BPH, noted fourfold and sixfold
increased age-specific risks of BPH surgery among all male
relatives and brothers, respectively, of cases. These inves-
tigators further estimated that 50% of men undergoing
surgery for BPH who were younger than 60 years of age
had a heritable form of disease [15]. These findings and
those of others have suggested an autosomal dominant
pattern of inheritance [16]. Men with inherited forms of
BPH tend to have larger prostates and younger age at onset
than men with sporadic BPH [17].
Monozygotic twin concordance rates of 63% and 26%
have been observed for LUTS and BPH, respectively, with
one study estimating that genetic factors may contribute as
much as 72% to the risk of high moderate or severe LUTS
among older men [18, 19].
Sex Steroid Hormones
Prostate tissue is composed of two basic elements: a
glandular element composed of secretory ducts and acini,
and a stromal element composed primarily of collagen and
smooth muscle. In BPH, unregulated cellular proliferation
leads to increased prostate volume and increased stromal
smooth muscle tone; increased prostate volume and stromal
smooth muscle tone in turn cause physical compression of
the urethra and mechanical obstruction of the bladder
outlet. In prostatic secretory cells, the hormone 5-α
reductase converts testosterone to DHT, a potent stimulator
of prostate growth that, in addition to being necessary for
prostate development, appears to play a central role in BPH
pathogenesis. Multiple studies have explored associations
of endogenous sex steroid hormones with BPH and LUTS.
Testosterone
At least seven observational studies have reported no
associations and five inverse associations of serum testos-
terone (total, bioavailable, or free) with BPH or LUTS [20,
21•, 22]. No studies to date have reported an increased risk
of BPH or LUTS with higher serum testosterone levels. A
prominent but theoretical concern of testosterone replace-
ment therapy is the potential for it to exacerbate BPH and
LUTS [23]. In this sense, these observations imply that
higher serum testosterone concentrations do not promote
BPH.
Dihydrotestosterone
Several studies have noted an increased risk of BPH with
increased serum concentrations of DHT and its metabolites.
In one recent prospective study of community-dwelling
men, those with the highest midlife levels of DHT had
nearly three times the risk of subsequent BPH compared
with those with the lowest levels [21•].
These results are consistent with those of three prior
studies of serum concentrations of two DHT metabolites:
Fig. 1 Broad categories of epidemiologic risk factors for benign
prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS)
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17b-diol-glucuronide and androstanediol glucuronide.
These metabolites are surrogate markers for DHT activity,
with higher concentrations indicating increased and lower
concentrations indicating decreased levels of DHT. Two
cross-sectional studies and one prospective study have
shown direct associations of these DHT metabolites with
BPH or LUTS [21•, 22].
The 5-α reductase inhibitors (finasteride and dutasteride)
decrease serum concentrations of DHT [24] and prevent
progression of clinical BPH [25]. However, it is not known
whether finasteride or dutasteride will prevent incident
BPH.
Estrogen
No clear patterns of estrogen, LUTS, and BPH have yet
emerged. Prior studies have reported positive, negative, and
null associations of endogenous estrogens with BPH and
LUTS [21•].
Other Hormones
Other sex steroid hormones also have not demonstrated
consistent links with LUTS or BPH. One study observed a
positive association of DHEAS (dehydroepiandrosterone
sulfate, a primary adrenal androgen with little intrinsic
androgenic activity) with BPH and two inverse associations
with LUTS [21•].
Lifestyle
A notable development in the epidemiology of BPH and
LUTS is the recognition that modifiable lifestyle factors
substantially influence the natural history of these
conditions. Accumulating data intimate that many of the
same metabolic disturbances associated with cardiovas-
cular disease—and the lifestyle factors that modulate
these disturbances—influence the risk of BPH and
LUTS. These observations are important because they
suggest the existence of modifiable pathways for BPH
and LUTS that may present novel targets for prevention
and treatment.
The Metabolic Syndrome and Cardiovascular Disease
The metabolic syndrome is a clinical constellation of
metabolic abnormalities—obesity, glucose intolerance,
dyslipidemia, and hypertension—that increases the risk of
cardiovascular disease and results primarily from dietary
and other lifestyle practices endemic to Westernized
societies [26].
In one cohort, men diagnosed with at least three
components of the metabolic syndrome had an 80%
increased prevalence of LUTS compared with those with
no components. Other studies have shown that men with
heart disease are at significantly increased risk of clinical
BPH and LUTS [27–29].
Obesity
Prior studies have consistently observed that increased
adiposity is positively associated with prostate volume—
that is, the greater the amount of adiposity, the greater the
prostate volume. Body weight, body mass index (BMI),
and waist circumference all have been positively associated
with prostate volume in multiple different study populations
[30–32]. In the Baltimore Longitudinal Study of Aging
cohort, for example, each 1-kg/m2 increase in BMI
corresponded to a 0.41-mL increase in prostate volume.
Moreover, obese (BMI ≥35 kg/m2) participants had a 3.5-fold
increased risk of prostate enlargement compared with non-
obese (BMI <25 kg/m2) participants [30]. A preponderance
of published epidemiologic evidence also demonstrates that
obesity increases the risks of BPH surgery, urinary symptom
progression, initiation of BPH medical therapy, and LUTS
[31–33].
Diabetes and Disruptions in Glucose Homeostasis
Disruptions in glucose homeostasis at multiple different
levels—from alterations in serum insulin growth factor
concentrations to diagnosis of clinical diabetes—are asso-
ciated with higher likelihoods of prostate enlargement,
BPH, and LUTS. Higher serum concentrations of insulin-
like growth factor-1 and insulin-like growth factor binding
protein-3 have been associated with increased risk of
clinical BPH and BPH surgery [34]. Physician-diagnosed
diabetes, increased serum insulin, and elevated fasting
plasma glucose have been associated with increased
prostate size and increased risks of prostate enlargement,
clinical BPH, BPH surgery, and LUTS in multiple different
cohorts cumulatively incorporating tens of thousands of
men [30, 31, 34–36].
Lipids
Relatively few data are available on potential associations
of lipids (high-density lipoprotein, low-density lipoprotein,
and triglycerides) with BPH and LUTS. At least five
studies have been conducted, with three showing positive
and two showing null associations [31, 35, 37].
Diet
There are some indications that macronutrients and
micronutrients may affect the risk of BPH and LUTS,
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although the patterns are somewhat inconsistent. For
macronutrients, increased total energy intake, energy-
adjusted total protein intake, red meat, fat, milk and dairy
products, cereals, bread, poultry, and starch potentially
increase the risks of clinical BPH and BPH surgery;
vegetables, fruits, polyunsaturated fatty acids, linoleic
acid, and vitamin D potentially decrease the risks of BPH
and LUTS [31, 38•]. With respect to micronutrients,
higher circulating concentrations of vitamin E, lycopene,
selenium, and carotene have been inversely associated
with BPH and LUTS [31, 38•, 39]; zinc has been
associated with increased and decreased risk [38•, 39].
Physical Activity
Increased physical activity and exercise have been
robustly and consistently linked with decreased risks of
BPH surgery, clinical BPH, histologic BPH, and LUTS
[31, 40]. A meta-analysis of 11 published studies (n=
43,083 men) indicated that moderate to vigorous physical
activity reduced the risk of BPH or LUTS by as much as
25% relative to a sedentary lifestyle, with the magnitude
of the protective effect increasing with higher levels of
activity [41].
Alcohol
Like exercise, moderate alcohol intake also appears to be
protective against multiple outcomes related to BPH [31].
However, unlike exercise, the same protective effect does
not appear to apply to LUTS. A meta-analysis of 19
published studies (n=120,091 men) observed up to a 35%
decreased likelihood of BPH among men who drank daily,
but an increased risk of LUTS [42].
Smoking
Although several studies support the existence of an
inverse protective effect of smoking on the risk of BPH
and LUTS, several others have reported no risk or
increased risk [31]. Thus, no definitive conclusions can
be drawn at this time.
Inflammation
Most observational studies suggest that inflammation is
intimately linked to the development of BPH and LUTS.
The mechanisms underpinning this relationship are
unclear. One potential explanation is that the metabolic
syndrome, which promotes systemic inflammation and
oxidative stress, mediates the connection between them
[43]. Inflammation has been implicated as a primary
stimulus for prostate carcinogenesis, and it is possible that
BPH represents a nonmalignant pathway of unregulated
prostate growth promoted by oxidative stress, inflamma-
tory mediators, and insulin growth pathways.
There are strong links between BPH and histologic
inflammation in surgical specimens, with the extent and
severity of the inflammation corresponding to the magni-
tude of prostate enlargement and BPH area [44–47]. Men
with LUTS are more likely to have higher serum C-reactive
protein, a robust marker of systemic inflammation [48],
while prior gonorrheal infection or prostatitis increase the
likelihood of BPH surgery and LUTS [49]. A history of
infection with gonorrhea, chlamydia, or trichomonosis
increases the risk of elevated prostate-specific antigen
[50]; high serum IgG antibody titers to cytomegalovirus,
herpes virus, human papilloma virus, and hepatitis are
associated with LUTS [51].
Conversely, inhibition of inflammatory pathways poten-
tially attenuates BPH risk. In one community cohort, men
who reported daily NSAID use experienced significantly
decreased risks of LUTS, low urinary flow rate, increased
prostate volume, and elevated prostate-specific antigen
[52].
Conclusions
In summary, BPH and LUTS are of significant impor-
tance to public health, affecting millions of older men
and contributing to billions of dollars in health care cost
each year. Current disease trends in the United States
suggest that the number of men suffering from these
conditions will swell markedly in the very near future.
The rapid aging of the US population, coupled with the
obesity and diabetes epidemics is poised to substantially
increase the prevalence of BPH and LUTS within the
general population and place even greater burdens on
finite health care resources. Although the relatively
immutable consequences of age and genetics factor
substantially in the development of BPH and LUTS,
many modifiable variables contribute as well—factors
that may be manipulated to delay onset, prevent
progression, or attenuate symptoms. Potential strategies
include inhibition of DHT synthesis with 5-α reductase
inhibitors, modulation of metabolic risk factors with
comprehensive lifestyle interventions incorporating diet
change and physical activity, and suppression of inflam-
matory pathways with NSAIDs.
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